Subscribe by Email

About the Blog

The Active Ingredient features expert insights and commentary from leaders of ZS Associates' global pharmaceuticals practice.

Search by Topic

see all

DNA-Based Data Is a Hot Commodity, and Pharma Is Buying

Posted by ZS Editors on Wed, Aug 01, 2018

As the pharmaceutical industry continues along the path to precision medicine, drug discovery efforts are just one aspect of the business that increasingly will be fueled by data. A flurry of deals, including GlaxoSmithKline’s $300-million, four-year investment in 23andMe, gives us a window into how pharma companies are forming partnerships and striking deals to tap into stores of data to identify new R&D targets and fill clinical trials.

Read More

Topics: pharma manufacturer, new partnerships, data acquisition strategy, patient data, genomic data, R&D targets

Subscribe to The Active Ingredient


Subscribe to receive email notifications whenever new blog posts are published.